Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Sanofi's INBRX-101?
INBRX-101 is a fusion protein commercialized by Sanofi, with a leading Phase II program in Alpha-1 Antitrypsin Deficiency (A1AD). According...